Epidemiology of Schizophrenia in Bulgaria

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00984373
First received: September 24, 2009
Last updated: February 2, 2010
Last verified: February 2010

September 24, 2009
February 2, 2010
September 2009
November 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00984373 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epidemiology of Schizophrenia in Bulgaria
Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria

The purpose of this study is to provide accurate, reliable information on schizophrenia clinical management in order to detect unmet medical needs of this disease in terms of:

  • Patient characteristics.
  • Diagnostic and treatment approaches: initial and subsequent.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

Primary Care Clinic

Schizophrenia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
440
November 2009
November 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with schizophrenia
  • Above 18 years
  • Signed Informed consent

Exclusion Criteria:

  • Below 18 years
  • Consent refused
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Bulgaria
 
NCT00984373
NIS-NBG-SER-2009/1
No
MC MD, AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP